Co-delivery of buparvaquone and polymyxin B in nanostructured lipid carrier for leishmaniasis treatment
ConclusionsThe developed NLC proved to be a promising formulation to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and macrophage targeting modified surface.Graphical abstract
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Antimicrobial Resistance | Bactrim | Infectious Diseases | Nanotechnology | Polymyxin B | Study